Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma

Vogelmeier, Claus; Kardos, Péter; Hofmann, Thomas; Canisius, Sebastian; Scheuch, G.; Muellinger, Bernhard; Nocker, Karlheinz; Menz, G; Rabe, Klaus F.

doi:10.1183/09031936.00152014

Cited by 23 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Die [304] oder dass es dadurch zu geringeren systemischen Nebenwirkungen im Vergleich zu einer äquivalenten Dosis eines oralen Glucocorticosteroids kommt [305,306]. Zudem ist diese Art der Behandlung im Verhältnis zur Therapie mit Dosieraerosolen bzw.…”

Section: Therapiestufe 5: Additive Therapieunclassified

S2k-Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma

Buhl

Bals

Baur³

et al. 2017

Pneumologie

View full text Add to dashboard Cite

ZusammenfassungDie vorliegende Leitlinie ist eine Neufassung und Aktualisierung der Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma, welche die bisher für den deutschen Sprachraum gültige Version aus dem Jahr 2006 ablöst. Die Fülle an neuen Erkenntnissen zur Pathophysiologie und zu den Phänotypen von Asthma und das erweiterte Spektrum an diagnostischen und therapeutischen Möglichkeiten bei dieser Erkrankung machte eine Neufassung und Aktualisierung notwendig. Es werden sowohl für Kinder und Jugendliche als auch für Erwachsene mit Asthma die aktuellen, Evidenz-basierten diagnostischen und therapeutischen Empfehlungen dargelegt.

show abstract

Section: Therapiestufe 5: Additive Therapieunclassified

S2k-Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma

Buhl

Bals

Baur³

et al. 2017

Pneumologie

View full text Add to dashboard Cite

show abstract

“…The dosing reliability of nebulisers has become far more accurate, with jet (pneumatic) and ultrasonic nebulisers giving way to portable vibrating mesh devices enhanced by the integration of software control. Indeed, intelligent nebulisers have been used in clinical trials to treat patients with asthma [35], where they pulse aerosols in greater amounts to the lungs with less waste and with deep lung delivery, and also in systemic delivery to treat patients with pulmonary hypertension [36]. …”

Section: What Are the Current Incentives Driving Inhaler Development mentioning

confidence: 99%

Is there room for further innovation in inhaled therapy for airways disease?

Biddiscombe

Usmani

2018

Breathe

View full text Add to dashboard Cite

Inhaled medication is the cornerstone in the treatment of patients across a spectrum of respiratory diseases including asthma and chronic obstructive pulmonary disease. The benefits of inhaled therapy have long been recognised but the most important innovations have occurred over the past 60 years, beginning with the invention of the pressurised metered dose inhaler. However, despite over 230 different device and drug combinations currently being available, disease control is far from perfect.Here we look at how innovation in inhaler design may improve treatments for respiratory diseases and how new formulations may lead to treatments for diseases beyond the lungs. We look at the three main areas where innovation in inhaled therapy is most likely to occur: 1) device engineering and design; 2) chemistry and formulations; and 3) digital technology associated with inhalers. Inhaler design has improved significantly but considerable challenges still remain in order to continually innovate and improve targeted drug delivery to the lungs. Healthcare professionals want see innovations that motivate their patients to achieve their goal of improving their health, through better adherence to treatment. Patients want devices that are easy to use and to see that their efforts are rewarded by improvements in their condition.Key pointsThe dictionary definition of innovation is the introduction of new things, ideas or ways of doing something. We show how this definition can be applied to inhaled therapy.We take a look at the past to see what drove innovation in inhaler design and how this has led to the current devices.We look at the current drivers of innovation in engineering, chemistry and digital technology and predict how this may translate to new devices.Can innovation help the healthcare professional manage their patients better?What does the patient expect from innovation in their device?Educational aimsTo understand the importance of inhaled medication in the treatment of lung diseases.To understand how innovation has helped advance some of the devices patients use today from basic and inefficient designs.To understand the obstacles that prevent patients from receiving optimal treatment from their inhalers.To understand how innovation in inhaler design can lead to improved treatment for patients and widen the range of diseases that can be treated via the inhaled route.

show abstract

“…In regard to this, vibrating mesh disk nebulisers, powered by a compressor and containing a microchip, control drug delivery to the patient and have an adaptive aerosol system to pulse the inhaled drug during the inhalation. This therefore leads to less dose wastage, positively impacting on patient's adherence 33 . A smart nebuliser system containing an electronic smart-card unit with an air compressor to accurately dose and target aerosol delivery, has also been developed lately, showing better efficacy and patients' adherence compared to standard nebulisers 34 .…”

Section: The Range Of Currently Available Inhaler Devicesmentioning

confidence: 99%

Demystifying Inhaler Use in Chronic Obstructive Airways Disease

Bonini¹,

Usmani²

2018

BRN

View full text Add to dashboard Cite

Chronic obstructive airways diseases afflict millions of people worldwide, being responsible for significant morbidity and mortality. Despite progresses in the understanding of the pathophysiological mechanisms and advances in the therapeutic interventions, neither asthma nor chronic obstructive pulmonary disease (COPD) can be cured as yet, although both diseases can be optimally controlled. Inhaler therapy plays a crucial role in achieving this and allows personalised treatment strategies to patients. However, satisfactory adherence and correct technique in the use of inhaler devices can be particularly challenging. The present review aims to present updated and evidence-based literature findings to shed light on the role and relevance of inhaler devices in chronic obstructive airways diseases and provide readers with clear information and advice about the use of inhalers in the variety of options available, to recognise the crucial inhaler errors and gain an insight with respect to recent innovation addressing the unmet needs in the field. (BRN Rev. 2018;4(4):304-18) Corresponding author: Matteo Bonini, m.bonini@imperial.ac.uk

show abstract

Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma

Cited by 23 publications

References 27 publications

S2k-Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma

S2k-Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma

Is there room for further innovation in inhaled therapy for airways disease?

Demystifying Inhaler Use in Chronic Obstructive Airways Disease

Contact Info

Product

Resources

About